



Cite this: *Nanoscale*, 2023, **15**, 17409

Two-dimensional molybdenum disulfide nanosheets evoke nitric oxide-dependent antibacterial effects†

Guotao Peng,^{a,b} Viviana González,^c Ester Vázquez,^{c,d} Jon O. Lundberg^e and Bengt Fadeel^{*,a}

Nanomaterials are currently being explored as novel antimicrobial agents. In this study, we first investigated the ability of two-dimensional (2D) molybdenum disulfide (MoS₂) nanosheets to trigger neutrophil extracellular traps (NETs) using neutrophil-differentiated HL-60 cells as well as primary human peripheral blood neutrophils. We then addressed whether the MoS₂ nanosheets themselves function as antibacterial agents. We found that MoS₂ and Na₂MoO₄ both triggered NETs, as evidenced by the quantification of neutrophil elastase (NE) activity and immunofluorescence staining of extracellular NE, as well as scanning electron microscopy. The release of NETs was found to be nitric oxide (NO)-dependent. We also found that the MoS₂ nanosheets but not the soluble salt prompted acellular NO production in the presence of NaNO₂. The acellular generation of NO, suggestive of nanozyme properties of the MoS₂ nanosheets, was demonstrated by electron paramagnetic resonance analysis. Electrochemical analysis using cyclic voltammetry confirmed the redox transition of the MoS₂ nanosheets. Finally, MoS₂ nanosheets inhibited the growth of *Escherichia coli* in the presence of sodium nitrate. Taken together, MoS₂ nanosheets triggered cellular effects as well as acellular antibacterial effects, and we provided evidence for nitrite reductase-like properties of MoS₂.

Received 28th June 2023,
Accepted 6th October 2023

DOI: 10.1039/d3nr03120a

rsc.li/nanoscale

1. Introduction

Bacterial infections pose a considerable burden on public health and novel approaches to overcome antimicrobial resistance are needed. Engineered nanomaterials can be used to deliver conventional antibiotics in a targeted manner or could be deployed as antibacterial agents *per se* to combat bacterial infections.¹ However, safety concerns may prevent clinical translation of novel materials, and careful assessment of their potential adverse effects on human health is required.²

Neutrophils, the most abundant white blood cells, play a key role in antimicrobial defense.³ Neutrophils can engulf bacteria leading to intracellular (oxidative and/or proteolytic)

killing of pathogens, but these cells also emit neutrophil extracellular traps (NETs) resulting in the extracellular killing of bacteria and fungi.⁴ NETs are web-like structure consisting of a scaffold of decondensed chromatin decorated with antimicrobial granule proteins including neutrophil elastase (NE) and myeloperoxidase (MPO).⁵ Previous work has suggested that NETs are selectively induced by large microorganisms (e.g., fungi) thereby preventing the dissemination of the offending pathogen.⁶ Interestingly, we previously found that large graphene oxide (GO) sheets were more effective in provoking NETs in neutrophils than small GO sheets.⁷ Moreover, small and large GO sheets were both susceptible to MPO-dependent degradation in NETs.⁸ However, the interactions of other 2D materials with neutrophils with respect to NETs have not been investigated previously. On the other hand, several studies have suggested that graphene and related materials, as well as other emerging 2D materials such as transition metal dichalcogenides (TMDs) and transition metal carbides and nitrides (MXenes), have antibacterial properties. For instance, Tu *et al.*⁹ provided experimental and theoretical evidence that GO sheets could extract lipids from bacterial membranes, suggesting a “physical” antibacterial effect. Moreover, Li *et al.*¹⁰ reported that hydrated GO sheets with a high density of carbon radicals were capable of killing drug-resistant bacteria. In a more recent study, graphdiyne oxide was found to kill

^aInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
E-mail: bengt.fadeel@ki.se

^bCollege of Environmental Science and Engineering, Tongji University, Shanghai, China

^cInstituto Regional de Investigación Científica Aplicada, Universidad de Castilla-La Mancha, Ciudad Real, Spain

^dFacultad de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha, Ciudad Real, Spain

^eDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

†Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3nr03120a>



Escherichia coli and *Staphylococcus aureus* through a reactive oxygen species (ROS) dependent mechanism.¹¹ Studies published in this journal have shown that 2D nanosheets of MoS₂ exert antibacterial effects, either through lipid extraction or through a ROS-dependent pathway.^{12,13} Ti-based MXenes also kill bacteria, possibly through a direct effect on bacterial membranes.¹⁴ However, the observed effects (frequently using very high doses of the materials, up to 500 µg mL⁻¹ or more) should be considered in light of the possible toxicity of the material towards host cells.

Nanomaterials, including 2D materials, may display enzyme mimetic properties including peroxidase-like or catalase-like effects.¹⁵ For instance, MoS₂ has been shown to exhibit activities of four major cellular antioxidant enzymes namely superoxide dismutase, catalase, peroxidase, and glutathione peroxidase.¹⁶ Interestingly, MoS₂ nanosheets were found to enhance CO₂ fixation in cyanobacteria through the reprogramming of metabolic pathways and the underlying mechanism was linked to the intrinsic peroxidase-like activity of MoS₂, whereas the soluble molybdate salt showed no such effects.¹⁷ However, investigations concerning the enzyme mimetic properties of 2D materials are mostly focused on the catalytic activity for ROS generation and on subsequent biological effects, whereas the capacity for reactive nitrogen species (RNS) production remains to be explored. Here, we set out to investigate the antibacterial effects of MoS₂. Using HL-60 cells and primary human neutrophils, we found that MoS₂ nanosheets and Na₂MoO₄ triggered NETs through a nitric oxide/peroxynitrite-dependent pathway. In addition, we showed that the intrinsic catalytic properties of MoS₂ nanosheets can be expanded to include nitrite reductase-like effects, as evidenced by antibacterial effects of MoS₂ towards *E. coli* in the presence of NaNO₂. The acellular generation of NO was confirmed by electron paramagnetic resonance (EPR) analysis. Our study sheds light on the interactions of MoS₂ with neutrophils and bacteria, and paves the way for developing novel antimicrobial agents using MoS₂.

2. Results

2.1. MoS₂ sheets trigger NET release in differentiated HL-60 cells

Few-layered MoS₂ nanosheets were synthesized as described previously.¹⁸ The lateral size as determined by TEM analysis was 136.00 ± 79.28 nm (Fig. S1A and B†). Importantly, the endotoxin content of the 2D sheets at 25 and 50 µg mL⁻¹ was zero or very low (well below the FDA-mandated limit for medical devices)¹⁹ (Fig. S1C†). To investigate the interaction of MoS₂ sheets with neutrophils, we first tested the ability of MoS₂ to trigger NETs in differentiated neutrophil-like HL-60 cells, a robust model of human neutrophils.²⁰ Neither MoS₂ nor the soluble molybdenum salt Na₂MoO₄ elicited any cytotoxicity (Fig. 1A). However, a significant increase of extracellular NE activity was observed after exposure to MoS₂, indicative of the release of NETs.²¹ In fact, at the highest dose (100 µg

mL⁻¹), MoS₂ was an even stronger trigger of NETs than the positive control, phorbol 12-myristate 13-acetate (PMA) (Fig. 1B). The molybdate salt also triggered a significant and dose-dependent increase of NE activity compared to untreated controls (Fig. 1B). To verify the presence of NETs, we performed immunofluorescence analysis.²¹ As shown in Fig. 1C, PMA, MoS₂, and Na₂MoO₄ triggered the formation of NETs revealed by the presence of extracellular fibers decorated with NE (green). Nuclei were counterstained with DAPI (blue). In the untreated control cells, intracellular NE staining was observed. Thus, using neutrophil-like HL-60 cells as a model, MoS₂ nanosheets and soluble molybdenum salt triggered NETs without causing cell death.

2.2. NET release induced by MoS₂ nanosheets is NO-dependent

The phorbol ester PMA activates NADPH oxidase to trigger NETs.²² Furthermore, NO, by augmenting free radical formation in neutrophils, also promotes the release of NETs.²³ We asked if NO is involved in the release of NETs in the current model. To this end, the NO donor, SNAP, and the NO scavenger, cPTIO, were deployed. Cellular NO production was determined by the DAF-FM-DA assay.²⁴ As expected, SNAP triggered significant NO production (more than 5-fold) compared to untreated control, and cPTIO significantly blocked NO generation (Fig. S2A†). Moreover, MoS₂ nanosheets triggered dose-dependent NO production, which was especially evident at the highest doses (50 and 100 µg mL⁻¹). Moreover, Na₂MoO₄ showed a similar trend in terms of NO production (Fig. S2A†). Notably, scavenging of NO with cPTIO led to a significant inhibition of NE activity in both MoS₂ and Na₂MoO₄ exposed cells, indicating that NO played a role in NET release (Fig. S2B†). Cellular NO and superoxide react rapidly to form peroxynitrite, and a previous study has shown that scavenging of peroxynitrite inhibited NO-induced NET formation.²⁵ We thus investigated the role of peroxynitrite in our model. First, we asked whether the MoS₂ nanosheets themselves were susceptible to peroxynitrite. To this end, MoS₂ nanosheets were incubated with SIN-1, a peroxynitrite donor previously shown to elicit the degradation of GO.²⁴ The dispersion of MoS₂ became completely translucent at 3 h (Fig. S3A†), suggestive of biotransformation, and further analysis revealed a red-shift of the Raman spectra (Fig. S3B†). Previous work has attributed this shift to doping,²⁶ and we thus interpret this as a sign of nitrogen doping of MoS₂. However, the two Raman modes E_{2g}¹ and A_{1g}, known to exhibit thickness dependence,²⁷ were not affected (Fig. S3B†). Next, we assessed peroxynitrite production in neutrophil-like HL-60 cells. To this end, the DAX-J2™ PON Green probe was used to detect peroxynitrite, and DPI and L-NAME, pharmacological inhibitors of NADPH oxidase and NOS, respectively, were applied (Fig. 2A). As shown in Fig. 2B, MoS₂ nanosheets as well as Na₂MoO₄ triggered peroxynitrite production which was blocked by DPI and L-NAME. PMA and SNAP were included as positive controls. We then applied the extracellular NE activity-based assay to test whether peroxynitrite production was required for NET release. As shown in






Fig. 1 Endotoxin-free MoS₂ nanosheets trigger NETs in neutrophil-differentiated HL-60 cells. (A) Cytotoxicity assessment in differentiated HL-60 cells by ATP content. (B) Quantification of NETs by NE activity. Differentiated HL-60 cells were exposed to PMA (50 nM), MoS₂, and Na₂MoO₄ (equivalent Mo) for 3 h at the indicated concentrations. Results are presented as the mean values \pm S.D. ($n = 3$). Student's *t*-test was used for the statistical significance compared to controls (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). (C) Visualization of NETs by immunofluorescence staining of NE. Neutrophil-like cells were exposed to MoS₂ (50 $\mu\text{g mL}^{-1}$) and Na₂MoO₄ (64 $\mu\text{g mL}^{-1}$) for 3 h. PMA (50 nM) served as positive control. NETs are clearly seen while NE remained intracellular in controls. Scale bars: 50 μm .

Fig. 2C, DPI and L-NAME were able to inhibit NE activity significantly in cells exposed to MoS₂ as well as Na₂MoO₄. These effects were further confirmed by immunofluorescence staining of NE, as shown in Fig. S4†. Collectively, our results demonstrated that NO is involved in the release of NETs in cells exposed to MoS₂. It is conceivable that MoS₂ nanosheets undergo biotransformation in contact with cells leading to the release of Mo ions which, in turn, contributes to the NET release.

2.3. MoS₂ nanosheets trigger NETs in primary neutrophils

To verify our findings using HL-60 cells, we investigated whether MoS₂ triggered NET release in primary human neutrophils. In line with the observations in differentiated HL-60 cells, MoS₂ and Na₂MoO₄ did not cause significant cytotoxicity in primary cells (Fig. S5A†), while a dose-dependent NET release was found as evidenced by a significant increase of extracellular NE activity (Fig. S5B†). The formation of NETs was confirmed by immunofluorescence staining which

revealed typical extracellular staining of NE (green) in the PMA, MoS₂, and Na₂MoO₄ exposed samples (Fig. 3). Furthermore, the MoS₂ nanosheets appeared to attach to the NETs (Fig. S6A†). To verify this, we performed SEM analysis of primary neutrophils exposed to PMA and MoS₂. We obtained clear evidence of web-like NETs, and it appeared that MoS₂ sheets were attached to the chromatin fibers (Fig. S6B†). Our results thus demonstrated that MoS₂ nanosheets as well as Na₂MoO₄ triggered NET release in primary human neutrophils in the absence of cell death.

2.4. MoS₂ nanosheets induce acellular bacterial killing

The experiments presented above suggested that MoS₂ may promote antibacterial effects through its effects on neutrophils, but any direct effects of MoS₂ on bacteria are difficult to evaluate using these models. To address whether MoS₂ nanosheets possess intrinsic antibacterial properties, and whether this could be linked to enzyme mimetic effects, we






Fig. 2 Role of peroxynitrite for NET release. (A) Cartoon showing the role of iNOS and the NADPH oxidase for the production of peroxynitrite. (B) Quantification of peroxynitrite production using the DAX-J2™ PON Green probe. The differentiated HL-60 cells were preincubated with DPI (10 μ M) and L-NAME (15 mM) for 30 min prior to the exposure to PMA (50 nM), SNAP (500 μ M), MoS₂ and Na₂MoO₄ at the indicated concentrations for 3 h. Peroxynitrite production was observed in cells exposed to MoS₂ and Na₂MoO₄, which was blocked by DPI and L-NAME. Two-way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, # p < 0.05; ## p < 0.01, ### p < 0.001, #### p < 0.0001; ns = no significance). (C) Role of peroxynitrite for NET release quantified by extracellular NE activity. DPI (10 μ M) and L-NAME (15 mM) were used to inhibit NADPH oxidase and NOS, respectively. Data shown as mean values \pm S.D. (n = 3). Two-way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = no significance). Refer to Fig. S2† for the effect of the NO scavenger cPTIO on NET production, and Fig. S4† for the visualization of NETs by immunofluorescence.






Fig. 3 Endotoxin-free MoS₂ nanosheets trigger NETs in primary human neutrophils. Visualization of NETs by immunofluorescence staining of NE. MoS₂ (50 μg mL⁻¹) and Na₂MoO₄ (64 μg mL⁻¹) triggered vigorous release of NETs in freshly isolated human neutrophils at 3 h. PMA (25 nM) was used as positive control. Scale bars: 20 μm. Refer to Fig. S5† for data on cell viability following exposure to MoS₂ and Na₂MoO₄ and Fig. S6† for further evidence of NETs in primary cells using SEM.

performed a series of acellular experiments. Specifically, we asked whether MoS₂ mimicked the properties of nitrite reductases (enzymes that catalyze the reduction of nitrite) with subsequent antibacterial effects. To test this, we explored the inhibition of bacterial growth by MoS₂ nanosheets using the

E. coli RK 4353 wild-type strain *versus* the mutant strain lacking nitrate reductases.²⁸ We first confirmed that the wild-type strain, but not the mutant, was able to utilize nitrate (NaNO₃) to promote its growth (Fig. S7†). We then determined the growth of *E. coli* in the presence or absence of MoS₂ or



Na_2MoO_4 with or without the addition of NaNO_3 (Fig. 4A–D). The results revealed that MoS_2 nanosheets inhibited the log-phase growth of wild-type *E. coli* in a dose-dependent manner (Fig. 4A), and the addition of NaNO_3 further enhanced the suppression of bacterial growth, particularly at the highest dose of MoS_2 ($200 \mu\text{g mL}^{-1}$) (Fig. 4B). In comparison, exposure to Na_2MoO_4 at equivalent Mo concentrations did not impact on bacterial growth (Fig. 4C), nor did the addition of NaNO_3 elicit obvious antibacterial effects (Fig. 4D). Interestingly, synergistic antibacterial effects were confirmed by supplementation with the NO donor, DETA NONOate (Fig. S8†). Furthermore, unlike the observations in the wild-type strain, MoS_2 nanosheets inhibited the growth of mutant *E. coli* only at the highest dose

($200 \mu\text{g mL}^{-1}$) (Fig. 4E), and the addition of NaNO_3 did not promote the antibacterial effects elicited by the MoS_2 nanosheets (Fig. 4F). However, the observed effects were modest and should be taken as indicative rather than definitive. Nevertheless, the differences between wild-type and mutant in the presence of NaNO_3 , as well as the differences between MoS_2 and Na_2MoO_4 , suggested that MoS_2 nanosheets might mimic nitrite reductases to produce NO, which consequently may account for the antibacterial effects. To verify our hypothesis that MoS_2 nanosheets catalyzed the production of NO from NaNO_2 (Fig. 5A) we investigated acellular NO production using two different approaches. First, incubation of MoS_2 nanosheets with nitrite (NaNO_2) generated detectable



Fig. 4 MoS_2 nanosheets elicit NO-dependent anti-bacterial effects. (A) MoS_2 nanosheets inhibited the bacterial growth of the *E. coli* RK 4353 wild-type (WT) strain in a dose-dependent manner. (B) The addition of sodium nitrate (10 mM) led to an enhanced suppression of bacterial growth by the MoS_2 nanosheets. (C) Incubation of Na_2MoO_4 (equivalent Mo) did not impact on the bacterial growth. (D) The addition of sodium nitrate (10 mM) with Na_2MoO_4 did not elicit the antibacterial effects seen for the MoS_2 nanosheets. MoS_2 nanosheets inhibited the bacterial growth of the *E. coli* RK 4353 mutant strain (lacking nitrate reductases) only at the highest dose ($200 \mu\text{g mL}^{-1}$) (E), and the addition of sodium nitrate (10 mM) did not promote the antibacterial effects of MoS_2 nanosheets on the mutant bacterial strain (F).



amount of NO (Fig. 5B), as determined by chemiluminescence.²⁹ In contrast, soluble Na₂MoO₄ did not produce NO with NaNO₂, indicating that the effects were nanomaterial/nanosheet specific. The generation of NO radicals was further confirmed by EPR analysis using the nitronyl nitroxide PTIO as the spin trap reagent. The reaction of PTIO with NO led to the typical EPR spectra of imino nitroxide and nitrogen dioxide (Fig. S9A and B†). Our results demonstrated that MoS₂ nanosheets mixed with NaNO₂ generated NO radicals in a dose (Fig. 6A and C) and time dependent manner (Fig. 6B and D). Cyclic voltammetry (CV) can be used to acquire information about the redox behavior of nanomaterials.^{30,31} To provide further evidence for the nanozyme-like properties of 2D MoS₂ nanosheets, we performed CV to ascertain electrochemical nitrite reduction. We found that the cathodic current was enhanced from 0.02 V (Fig. 6E) to 0.17 V (Fig. 6F) in the presence of nitrite (NaNO₂) (and refer to Fig. S10† for the individual CV scans). In summary, the 2D MoS₂ nanosheets seemed to possess enzyme mimetic properties.

3. Discussion

In the present study, we investigated the potential antibacterial properties of MoS₂ nanosheets and the underlying mechanisms using cellular and acellular systems. We demonstrated for the first time that MoS₂ triggered the release of anti-bacterial NETs, and this was shown to occur through an NO/peroxynitrite-dependent pathway. Importantly, MoS₂ triggered the release of NETs in neutrophil-differentiated HL-60 cells as well as in primary human neutrophils at doses that were non-cytotoxic towards these cell types. We also found that the soluble molybdenum salt (Na₂MoO₄) triggered NETs. This is consistent with a recent study showing that sodium molybdate induced extracellular trap formation in heterophils in the absence of cell death.³² In addition, a direct antibacterial

effect of MoS₂ nanosheets was demonstrated in the present study, and evidence was provided for NO production, attributed to the enzyme mimetic properties of MoS₂. Indeed, EPR analysis as well as electrochemical analysis supported the conclusion that 2D MoS₂ nanosheets display enzyme-like activity, and these effects were not seen for the soluble Mo salt. Non-enzymatic mechanisms such as a direct physical damage of bacterial membranes, or a combination of physical effects and metabolic reprogramming,³³ cannot be ruled out, as the effects on bacterial growth were observed in wild-type and mutant bacteria in the absence of NaNO₃. However, in the presence of NaNO₃, the impact of MoS₂ on *E. coli* was more pronounced, and the results point to a role of NO in bacterial killing. The present study thus points to a novel antibacterial mechanism which exploits the propensity of nitrate-reducing bacteria to generate nitrite, which is then transformed by MoS₂ to NO. Taken together, these results expand the repertoire of so-called nanozyme (enzyme mimetic) activities of MoS₂.³⁴ Thus, while previous studies emphasized peroxidase-like, catalase-like, and superoxide dismutase-like properties, our study is the first to provide evidence of a nitrite reductase-like effect. However, it is important to recognize that a true “nanozyme” should have effects similar to enzymes, *i.e.*, efficient catalytic activity, and a specific mechanism of action.³⁵ Therefore, we prefer the term “nanozyme-like”.

NETs are tasked with the clearance of invading pathogens including bacteria, and the involvement of NADPH oxidase-dependent and independent pathways are well documented.^{22,36} Furthermore, RNS (*i.e.*, NO and peroxynitrite) have also been shown to enhance the release of NETs.^{23,25} In our previous studies, we could show that GO sheets triggered NETs in a size-dependent manner inasmuch as small GO sheets triggered canonical NADPH oxidase-dependent release of NETs while large GO sheets triggered NETs in an NADPH oxidase-independent manner.⁷ It is pertinent to note that carbon-based nanomaterials are also susceptible to




Fig. 5 MoS₂ nanosheets are capable of producing NO in an acellular setting. (A) Cartoon showing the nitrate-nitrite-dependent reductive route of NO production. Bacterial nitrate reductases transform nitrate to nitrite, and the putative nitrite reductase-like properties of MoS₂ nanosheets transform nitrite to NO. (B) Chemiluminescence detection of acellular NO production. MoS₂ nanosheets (1 mg mL⁻¹) but not Na₂MoO₄ salt (1.28 mg mL⁻¹) catalyzed NaNO₂ (1 mM) to produce NO.






Fig. 6 MoS₂ nanosheets produce NO radicals: evidence for nanozyme properties. (A–D) EPR analysis of NO radicals (and refer to Fig. S9†). Two doses of MoS₂ (high and low) (1 mg mL⁻¹ and 200 μg mL⁻¹) were mixed with NaNO₂ at the dose of 10 mM. The spin trap PTIO (100 mM) was added immediately prior to the analysis, and EPR spectra were captured at 5 min and 10 min. (A and B) MoS₂ nanosheets (1 mg mL⁻¹) mixed with sodium nitrite (NaNO₂) (10 mM) generated NO radicals captured by the spin trap, PTIO (100 mM) at 5 min (A) and 10 min (B). (C and D) MoS₂ (200 μg mL⁻¹) mixed with NaNO₂ (10 mM) generated NO radicals captured by PTIO at 5 min (C) and 10 min (D) albeit not to the same extent as high-dose MoS₂. Redox transition of MoS₂ nanosheets in the absence (E) or presence (F) of nitrite as evidenced by cyclic voltammetry. Upon addition of nitrite, the cathodic current was enhanced from 0.02 V to 0.17 V (arrows), as a result of the redox process.



degradation through NADPH oxidase and/or iNOS-driven pathways,^{8,21,24,37,38} thus suggesting reciprocal interactions between nanomaterials and the immune system.³ However, in the present study, the release of NETs is shown to be Mo-dependent, suggesting a different mechanism (in other words, not size-dependent as shown for GO).

Cellular NO generation occurs *via* the oxidative route, with the involvement of nitric oxide synthase (NOS), or *via* the nitrate-nitrite-dependent reductive route.³⁹ NOS enzymes produce NO from arginine, and neutrophils as well as classically activated macrophages²⁴ express inducible NOS (iNOS), which accounts for the NO production observed in cells encountering MoS₂ nanosheets. The fact that the NO scavenger cPTIO, as well as a NADPH oxidase inhibitor (DPI) and a NOS inhibitor (L-NAME) prevented NET formation in our model supports the conclusion that MoS₂ nanosheets triggered NETs through an NO/peroxynitrite-driven pathway. It is worth noting that early work implicated NO in NET release insofar as L-NAME was found to reduce NET release in mouse neutrophils.⁴⁰ Moreover, the NO donor SNAP was shown to trigger NETs.^{23,25} However, NADPH oxidase activity was required to release NETs upon stimulation with NO, thus implying a role for peroxynitrite.²⁵ We confirmed here that SNAP triggered release of NETs in neutrophils. Nevertheless, the involvement of ROS in NET formation cannot be dismissed.²² Indeed, this may provide an explanation for the observation that SNAP triggered the highest level of NO, but prompted less NETs as compared to the MoS₂ nanosheets. Thus, while NET release may be regarded as an NO-dependent process, its metabolite, peroxynitrite appears to be the key factor in NET release from cells exposed to MoS₂.

NETs were initially shown to play a pivotal role in host defense by immobilizing and destroying pathogens (bacteria as well as fungi).^{5,41} However, it is pertinent to note that excessive or inadvertent NET formation, or a lack of clearance of NETs by macrophages or other phagocytic cells,⁴² is a risk factor for autoimmune disease and thrombosis and may lead to vascular occlusion.⁴³ In other words, while NETs display antimicrobial properties, they may be viewed as a double-edged sword of innate immunity.⁴⁴ Moreover, some authors have coupled the release of NETs with a necrotic cell death dubbed NETosis.⁴⁵ However, in the present study, the NET-releasing cells remained viable. Further studies, including studies in relevant animal models, are required to understand the consequences of MoS₂-driven NET release.

Interestingly, all members of the molybdenum (Mo)-dependent enzyme family have been shown to reduce nitrite to NO.⁴⁶ Mao *et al.*⁴⁷ showed in a very recent study that Na₂MoO₄ triggered NO production in ovarian cancer cells, and the authors found that the simultaneous silencing of *SUOX*, *AOX1*, and *mARC1* in the SKOV3 cell line lowered the Na₂MoO₄-induced NO levels, implying a role for these Mo-dependent enzymes, while the silencing of *XDH* or *mARC2* had no impact on NO production. Thus, bioavailable Mo could yield NO through more than one pathway. Cao *et al.*⁴⁸ reported that MoS₂ may undergo biotransformation (oxidation) *in vivo*, donating its Mo

towards the synthesis of Mo-dependent enzymes in the liver. However, NO production was not investigated in the latter study. The present data support the view that MoS₂-triggered NO generation in neutrophils occurs through an iNOS-dependent pathway. However, it is necessary to consider the reductive pathway of NO production, and “the versatile redox chemistry of molybdenum”⁴⁹ to understand the acellular MoS₂-triggered production of NO (in the presence of nitrite).

Living organisms use nitrite for a variety of different purposes.⁵⁰ One of us previously demonstrated that acidification of nitrite-rich urine resulted in the killing of nitrate-reducing bacteria.²⁸ Here, we explored the enzyme mimetic activity of MoS₂ nanosheets, specifically whether the nanosheets could function as nitrite reductases, and the subsequent impact on bacterial growth. Taking advantage of wild-type *E. coli* and a mutant strain lacking nitrate reductases, we could show that MoS₂ nanosheets elicited more pronounced bacterial inhibition in wild-type bacteria in the presence of sodium nitrate (NaNO₃). Moreover, EPR analysis provided evidence for the presence of NO radicals in the system. Importantly, soluble Na₂MoO₄ did not evoke similar effects, which further suggested that the enzyme-like activity evidenced here is a 2D material-specific property. MoS₂ was shown previously to act as a catalyst for denitrification, thus facilitating the electrochemical reduction of nitrate/nitrite to ammonia.⁵¹ Previous work has also shown that the catalase-like nanozyme activities of MoS₂ are more pronounced under acidic conditions.¹⁶ The present acellular studies were performed at neutral pH. Further studies are needed to determine whether the nitrite reductase-like properties of MoS₂ nanosheets are pH-dependent. As noted above, acidification of urine is known to promote the killing of nitrate-reducing bacteria likely due to a conversion of nitrite to bactericidal nitrogen oxides.²⁸ It may also be important to consider the impact of pH on the nanosheets themselves. Indeed, Wang *et al.*⁵² demonstrated in a comprehensive study that MoS₂ may undergo oxidative dissolution with kinetics that depend on pH.

The present study is a proof-of-concept study. Nevertheless, we foresee several potential applications of MoS₂ nanosheets including in the clinical setting, *e.g.*, coating of catheters or medical implants using MoS₂ nanosheets to combat infections and prevent the formation of biofilms. Moreover, nanozyme-like MoS₂ nanosheets could potentially be incorporated in wound dressings, perhaps as hydrogels, as shown recently in an elegant study by Sang *et al.*⁵³ Beyond such biomedical applications, MoS₂ could also be integrated into water filtration membranes used in environmental remediation processes.⁵⁴ To our knowledge, the antibacterial properties of MoS₂ nanosheets have not been fully exploited in this setting.

4. Conclusions

Our study has provided evidence that MoS₂ nanosheets evoke NO-dependent antibacterial effects. These effects occurred indirectly through effects on neutrophils, leading to the



release of NETs, and directly by virtue of enzyme mimetic properties. Hence, in the cellular system, NO/peroxynitrite contributed to the release of NETs, which are known to kill bacteria (and fungi). This was also observed for sodium molybdate. In the acellular system, NO generated *via* the nitrate-nitrite-dependent reductive route contributed to the antibacterial effects of MoS₂. The present study is thus the first to suggest the possibility of nitrite reductase-mimicking properties of MoS₂.

5. Experimental section

5.1. Synthesis and characterization of MoS₂

The 2D MoS₂ nanosheets were synthesized according to a previously established protocol.¹⁸ Briefly, bulk molybdenum disulfide (Sigma-Aldrich) was used as the precursor material and glycine (Sigma-Aldrich) was used as the exfoliating agent. The mechanochemical process was conducted in a ball-milling machine (Retsch pm100) at room temperature and air atmosphere for 15 min at the speed of 250 rpm. After the milling treatment, the resulting solid mixtures were dispersed in water and dialyzed to remove the glycine. Dry powder samples were obtained after lyophilization at -80 °C at a pressure of 0.005 bar. The powders were stored at room temperature and dispersions were obtained by dispersing in water, followed by water bath sonication (10 s cycles for 2 min). TEM analyses were performed on stable dispersions of MoS₂ diluted as necessary and dip-casted on Lacey copper grids (3.00 mm, 200 mesh), coated with carbon film, and dried under vacuum. Samples were investigated using a HR-TEM JEOL 2100 at an accelerating voltage of 100 kV. Further characterization results for as-produced samples are reported in González *et al.*¹⁸ and are not replicated here. For Raman spectroscopy, see below. Sodium molybdate (Na₂MoO₄) (CAS number: 7631-95-0) was obtained from Sigma. The stock solution was prepared at a concentration of 1.280 mg mL⁻¹ (*i.e.*, the equivalent amount of Mo present in 1 mg mL⁻¹ MoS₂) in endotoxin-free ultrapure water.

5.2. Raman spectroscopy

For Raman spectroscopy,⁵⁵ MoS₂ nanosheets exposed or not to the peroxynitrite donor, 3-morpholinopyridone hydrochloride (SIN-1) (Sigma-Aldrich) were deposited by drop-casting on SiO₂/Si substrate, blow dried by N₂ gas, washed three times in dH₂O, followed by Raman analysis which was carried using the Witec Alpha 300 RAS instrument. The 532 nm laser optimized to 3 mW to minimize heating was used to acquire data. Data shown are the average of at least 5 spectra per sample.

5.3. Limulus amoebocyte lysate assay

Endotoxin content of the MoS₂ samples was evaluated using the Pierce™ Chromogenic Endotoxin Quant Kit (ThermoFisher Scientific). Briefly, MoS₂ nanosheets (25 and 50 μg mL⁻¹) were mixed with LAL solution and incubated at 37 °C for 10 min. The absorbance values were captured at

405 nm using a Tecan Infinite® F200 plate reader (Stockholm, Sweden). MoS₂ (50 μg mL⁻¹) spiked with lipopolysaccharides (LPS) (0.5 EU mL⁻¹) was included as an interference test (not shown).

5.4. HL-60 cell differentiation and culture

The human acute promyelocytic leukemia cell line HL-60 (ATCC-CCL-240) was maintained in phenol red-free RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 U mL⁻¹ penicillin, 100 μg mL⁻¹ streptomycin, and 10% heat-inactivated fetal bovine serum (FBS) (Sigma). In order to achieve neutrophil-like differentiation,²⁰ the cells were seeded at 0.5 × 10⁶ cells per mL in cell medium supplemented with 1.25% DMSO for 5 days. The medium was changed after 3 days.

5.5. Human neutrophil isolation and culture

Neutrophils were isolated from buffy coats obtained from healthy adult blood donors (Karolinska University Hospital, Stockholm, Sweden) as previously described.⁸ In brief, neutrophils were separated by density gradient centrifugation with Lymphoprep™ (Stemcell™ Technologies, Sweden). The neutrophil layer was then subjected to sedimentation in 5% dextran solution, followed by hypotonic lysis of residual erythrocytes using deionized water. Isolated neutrophils were maintained in phenol red-free RPMI-1640 culture medium (Sigma) supplemented with 2 mM L-glutamine, 100 U mL⁻¹ penicillin, and 100 mg mL⁻¹ streptomycin without fetal bovine serum.

5.6. Cytotoxicity assessment

Cell viability assessment following MoS₂ and Na₂MoO₄ exposure was evaluated based on the ATP content by using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Cells were seeded in 96-well plates (1 × 10⁶ cells per mL) in phenol red-free RPMI-1640 medium supplemented with L-glutamine, penicillin, and streptomycin. Cells were exposed for 3 h to MoS₂ nanosheets (1, 5, 25, 50, and 100 μg mL⁻¹) and to the equivalent concentration of Na₂MoO₄ (1.28, 6.4, 32, 64, and 128 μg mL⁻¹). PMA (Sigma-Aldrich) was used as a positive control (50 nM in differentiated HL-60 cells²⁰ and 25 nM in primary neutrophils⁴²). Then, CellTiter-Glo® reagent was added, and plates were shaken for 2 min and incubated at room temperature for 10 min. Luminescence values were recorded using a Tecan Infinite® F200 plate reader.

5.7. Neutrophil elastase activity

NE activity in the cell culture supernatants was analyzed as described previously.⁷ Briefly, cells were seeded in 96-well plates at a density of 1 × 10⁶ cells per mL. After 3 h of exposure to MoS₂ (1, 5, 25, 50 and 100 μg mL⁻¹) and Na₂MoO₄ (1.28, 6.4, 32, 64, and 128 μg mL⁻¹), the supernatants were collected after intensive pipetting and centrifuged at 1600 rpm for 5 min. PMA was used as a positive control for the induction of NETs. The supernatants were incubated with 5 μg mL⁻¹ of DNase I (Sigma-Aldrich) for 15 min at room temperature to



digest the DNA,⁵⁶ followed by incubation with the elastase substrate *N*-(methoxysuccinyl)-Ala-Ala-Pro-Val 4-nitroanilide (200 μM) (Sigma-Aldrich) in the assay buffer (Tris 0.1 M, NaCl 0.5 M, pH 8). After incubation for 3 h at room temperature, the absorbance at 405 nm was recorded using a Tecan Infinite® F200 plate reader. The NE activity was normalized to untreated controls. To investigate the role of NO and peroxynitrite, the NO donor, *S*-nitroso-*N*-acetylpenicillamine (SNAP, 500 μM) (Sigma-Aldrich) and the NO scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (cPTIO, 250 μM) were used, and diphenyleneiodonium chloride (DPI, 10 μM), and *N* ω -nitro-*L*-arginine methyl ester hydrochloride (*L*-NAME, 15 mM) (all from Sigma-Aldrich) were used to block NADPH oxidase and iNOS, respectively. For these experiments, cells were pre-incubated with cPTIO, DPI and *L*-NAME for 30 min prior to the exposure to MoS₂ nanosheets, Na₂MoO₄, and positive controls. The supernatants were collected, and NE activity was determined as described above.

5.8. Confocal microscopy of NETs

To visualize NETs, we performed confocal microscopy as described.²⁰ Sterilized coverslips were coated with poly-*L*-lysine (Sigma-Aldrich) for 20 min, washed three times with PBS, and dried at room temperature. Differentiated HL-60 cells or primary neutrophils were seeded on the coverslips at a density of 1×10^6 cells per mL for 1 h. Then, HL-60 cells were exposed to PMA (50 nM), MoS₂ (5 and 50 $\mu\text{g mL}^{-1}$) and Na₂MoO₄ (6.4 and 64 $\mu\text{g mL}^{-1}$) for 3 h. For DPI and *L*-NAME groups, the cells were pre-incubated with DPI (10 μM) and *L*-NAME (15 mM) for 30 min. For primary neutrophils, cells were exposed to the PMA (25 nM), MoS₂ (50 $\mu\text{g mL}^{-1}$) and Na₂MoO₄ (64 $\mu\text{g mL}^{-1}$) for 3 h. After the exposure, the slides were fixed with 4% paraformaldehyde solution for 30 min at RT, followed by blocking for 30 min in 2% BSA-PBS solution. The cells were then stained using a mouse anti-human NE antibody (sc-53388, Santa Cruz Biotechnology) (1:100 in 2% BSA-PBS) at 4 °C overnight. The secondary antibody staining was performed using the Alexa-488 goat anti-mouse antibody (1:500 in 2% BSA-PBS, ThermoFisher Scientific) for 1 h at room temperature. The slides were then washed three times with PBS and mounted with ProLong™ Gold Antifade Mountant with DAPI (ThermoFisher Scientific). The confocal images were captured using a Zeiss LSM880 confocal microscopy (ZEISS).

5.9. Scanning electron microscopy

Primary neutrophils (1×10^6 cells per mL) were seeded in 24-well plates on poly-*L*-lysine coated coverslips. After 1 h, cells were exposed for 3 h to PMA (25 nM), MoS₂ (50 $\mu\text{g mL}^{-1}$), or Na₂MoO₄ (64 $\mu\text{g mL}^{-1}$). SEM was then performed as described.⁷ Briefly, slides were fixed with 2.5% glutaraldehyde in 0.1 M PBS, rinsed in dH₂O, placed in 70% ethanol for 10 min, followed by 95% ethanol for 10 min, absolute ethanol for 15 min, and, finally, acetone. Samples were dried with a critical point dryer (Balzer, CPD 010) and CO₂, mounted on an aluminum stub, coated with carbon (Bal-Tec MED 010), and

analyzed with an Ultra 55 field emission microscope (Zeiss) at 3 kV.

5.10. NO and peroxynitrite detection

NO production in differentiated HL-60 cells was determined by the DAF-FM-DA assay (Sigma-Aldrich) as described previously.⁵⁷ Cells were preincubated for 30 min with cPTIO (250 μM) to scavenge NO. After 3 h exposure to PMA (50 nM), SNAP (500 μM), MoS₂ (1, 5, 25, 50 and 100 $\mu\text{g mL}^{-1}$) and Na₂MoO₄ (1.28, 6.4, 32, 64, and 128 $\mu\text{g mL}^{-1}$), cells were washed with PBS and incubated with DAF-FM-DA (10 μM) for 60 min. Then, cells were washed with PBS to remove excess probe and incubated for 30 min to allow complete de-esterification. The fluorescence signal was captured at the excitation and emission wavelengths of 495 and 515 nm using a Tecan Infinite® F200 plate reader. Peroxynitrite generation in neutrophil-like HL-60 cells was determined using the DAX-J2™ PON Green probe (AAT BioQuest, Sunnyvale, CA), as previously described.²⁴ DPI (10 μM) and *L*-NAME (15 mM) were used to block the NADPH oxidase and iNOS, respectively. After 3 h of exposure to PMA, MoS₂, or Na₂MoO₄, cells were incubated with the fluorescent probe for 2 h in the dark at 37 °C. The fluorescence signal was captured at the excitation and emission wavelengths of 490 and 530 nm using a Tecan Infinite® F200 plate reader.

5.11. Bacterial growth inhibition

To assess the impact of MoS₂ nanosheets *versus* Na₂MoO₄ on bacterial growth, *E. coli* RK 4353 wild-type (WT) and mutant strains lacking nitrate reductases were used.⁵⁸ The *E. coli* strains were a generous gift from Jeff A. Cole, University of Birmingham, UK. The bacterial solutions were prepared by preincubation of two colonies in 4 mL Mueller-Hinton (MH) broth (Sigma-Aldrich) for 6 h to give a concentration of 10^8 CFU mL⁻¹. Then, a 1:100 dilution of bacterial solution was prepared with MoS₂ and Na₂MoO₄ to yield the final concentrations of MoS₂ (25, 50, 100, and 200 $\mu\text{g mL}^{-1}$) and Na₂MoO₄ (32, 64, 128, and 256 $\mu\text{g mL}^{-1}$). NaNO₃ (10 mM) (Sigma-Aldrich) and DETA NONOate (100 μM) (Sigma-Aldrich) was supplied as indicated. The bacterial solutions for each condition were transferred to flat-bottom microwell plates (Corning) using three wells (technical replicates) per condition. Bacterial growth was measured continuously for 800 min at 37 °C and absorbance values at 540 nm was recorded every 20 min in a computerized incubator (Spectra Max 340, Molecular Devices), as previously described by us.²⁸ MoS₂ nanosheets were included as a reference and absorbance values were subtracted accordingly.

5.12. Chemiluminescence analysis

Acellular NO production was determined using a chemiluminescence NO analyzer (Eco Physics, Dürnten, Switzerland).²⁹ Specifically, MoS₂ (1 mg mL⁻¹) or Na₂MoO₄ (1.28 mg mL⁻¹) was mixed with sodium nitrite (NaNO₂) (1 mM) (Sigma-Aldrich) in a syringe and incubated for 2 min. The air space was set as 50 mL. After 2 min incubation, 40 mL of the air was



taken by another syringe and injected to the chemiluminescence NO detector for NO quantification. The NO detection limit was 1 ppb.

5.13. EPR analysis for NO detection

The acellular NO radical formation was determined by EPR analysis.⁵⁹ Specifically, MoS₂ nanosheets (200 μg mL⁻¹ and 1 mg mL⁻¹) and NaNO₂ (10 mM) were mixed immediately prior to the analysis. The nitronyl nitroxide, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) (100 mM) (Sigma-Aldrich) was added immediately to detect NO radicals.⁶⁰ The EPR spectra were captured at 5 min and 10 min after adding PTIO using the Bruker spectrometer A300-10/12 (Mannheim, Germany). In addition, the EPR spectrum of PTIO alone was captured as a reference.

5.14. Cyclic voltammetry

A one-compartment, three-electrode system was employed for the electrochemical nitrite reduction experiments. The electrolyte consisted of a 0.5 M Na₂SO₄ aqueous solution (pH = 6.8). NaNO₂ was added to the electrolyte at a final concentration of 0.1 M. Electrochemical measurements were conducted using a commercial electrochemical workstation (CHI-760E, Shanghai Chenhua Instrument Co., Ltd, China). Pt wire and a saturated calomel electrode were utilized as counter and reference electrodes, respectively. The working electrode was designed using the MoS₂ sample coated on the fluorine-doped tin oxide conductive glass surface. The measurements were performed by scanning from the resting potential at a scanning rate of 2 mV s⁻¹. The CV scans were conducted three times to examine the repeatability of the electrochemical properties (refer to Fig. S10† for individual scans).

5.15. Statistical analysis

Three independent experiments were performed using the HL-60 cell line and experiments with primary neutrophils were performed using cells isolated from three individual donors. The results shown are the mean values ± S.D. and the statistical analysis was performed using Student's *t*-test and two-way ANOVA (GraphPad, Prism 8.0.2). Statistically significant differences were considered when *p* < 0.05.

Author contributions

G. P. performed experiments, analyzed data, and drafted the paper; V. G. performed experiments; E. V. supervised the work, and analyzed data; J. O. L. supervised the work, and analyzed data; B. F. coordinated the study, supervised the work, analyzed data, and edited the paper, and all co-authors approved the final version of the paper.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

Supported by the European Commission through the Graphene Flagship (grant agreement no. 881603) (B. F., E. V.). EPR and CV studies were supported by the Fundamental Research Funds for the Central Universities (G. P.). We thank Lars Haag, Electron Microscopy Core Facility, Karolinska Institutet, for assistance with SEM, Illia Dobryden, RISE Research Institutes of Sweden, for assistance with Raman, and Carina Nihlen, Department of Physiology and Pharmacology, Karolinska Institutet, for assistance with the bacterial growth inhibition studies.

References

- 1 J. M. V. Makabenta, A. Nabawy, C. H. Li, S. Schmidt-Malan, R. Patel and V. M. Rotello, *Nat. Rev. Microbiol.*, 2021, **19**, 23–36.
- 2 B. Fadeel, L. Farcas, B. Hardy, S. Vázquez-Campos, D. Hristozov, A. Marcomini, I. Lynch, E. Valsami-Jones, H. Alenius and K. Savolainen, *Nat. Nanotechnol.*, 2018, **13**, 537–543.
- 3 G. Peng and B. Fadeel, *Adv. Drug Delivery Rev.*, 2022, **188**, 114422.
- 4 V. Papayannopoulos, *Nat. Rev. Immunol.*, 2018, **18**, 134–147.
- 5 V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y. Weinrauch and A. Zychlinsky, *Science*, 2004, **303**, 1532–1535.
- 6 N. Branzk, A. Lubojemska, S. E. Hardison, Q. Wang, M. G. Gutierrez, G. D. Brown and V. Papayannopoulos, *Nat. Immunol.*, 2014, **15**, 1017–1025.
- 7 S. P. Mukherjee, B. Lazzaretto, K. Hultenby, L. Newman, A. F. Rodrigues, N. Lozano, K. Kostarelos, P. Malmberg and B. Fadeel, *Chem*, 2018, **4**, 334–358.
- 8 S. P. Mukherjee, A. R. Gliga, B. Lazzaretto, B. Brandner, M. Fielden, C. Vogt, L. Newman, A. F. Rodrigues, W. Shao, P. M. Fournier, M. S. Toprak, A. Star, K. Kostarelos, K. Bhattacharya and B. Fadeel, *Nanoscale*, 2018, **10**, 1180–1188.
- 9 Y. Tu, M. Lv, P. Xiu, T. Huynh, M. Zhang, M. Castelli, Z. Liu, Q. Huang, C. Fan, H. Fang and R. Zhou, *Nat. Nanotechnol.*, 2013, **8**, 594–601.
- 10 R. Li, N. D. Mansukhani, L. M. Guiney, Z. Ji, Y. Zhao, C. H. Chang, C. T. French, J. F. Miller, M. C. Hersam, A. E. Nel and T. Xia, *ACS Nano*, 2016, **10**, 10966–10980.
- 11 Y. Zhang, W. Liu, Y. Li, Y. W. Yang, A. Dong and Y. Li, *iScience*, 2019, **19**, 662–675.
- 12 X. Yang, J. Li, T. Liang, C. Ma, Y. Zhang, H. Chen, N. Hanagata, H. Su and M. Xu, *Nanoscale*, 2014, **6**, 10126–10133.
- 13 R. Wu, X. Ou, R. Tian, J. Zhang, H. Jin, M. Dong, J. Li and L. Liu, *Nanoscale*, 2018, **10**, 20162–20170.
- 14 K. Rasool, M. Helal, A. Ali, C. E. Ren, Y. Gogotsi and K. A. Mahmoud, *ACS Nano*, 2016, **10**, 3674–3684.
- 15 M. Liang and X. Yan, *Acc. Chem. Res.*, 2019, **52**, 2190–2200.



- 16 X. Zhang, S. Zhang, Z. Yang, Z. Wang, X. Tian and R. Zhou, *Nanoscale*, 2021, **13**, 12613–12622.
- 17 S. Chen, N. Shi, M. Huang, X. Tan, X. Yan, A. Wang, Y. Huang, R. Ji, D. Zhou, Y. G. Zhu, A. A. Keller, J. L. Gardea-Torresdey, J. C. White and L. Zhao, *ACS Nano*, 2021, **15**, 16344–16356.
- 18 V. J. González, A. M. Rodríguez, I. Payo and E. Vázquez, *Nanoscale Horiz.*, 2020, **5**, 331–335.
- 19 M. Himly, M. Geppert, S. Hofer, N. Hofstätter, J. Horejs-Höck and A. Duschl, *Small*, 2020, **16**, e1907483.
- 20 A. Khandagale, B. Lazzaretto, G. Carlsson, M. Sundin, S. Shafeeq, U. Römling and B. Fadeel, *J. Leukocyte Biol.*, 2018, **104**, 1199–1213.
- 21 C. Farrera, K. Bhattacharya, B. Lazzaretto, F. T. Andon, K. Hultenby, G. P. Kotchey, A. Star and B. Fadeel, *Nanoscale*, 2014, **6**, 6974–6983.
- 22 T. A. Fuchs, U. Abed, C. Goosmann, R. Hurwitz, I. Schulze, V. Wahn, Y. Weinrauch, V. Brinkmann and A. Zychlinsky, *J. Cell Biol.*, 2007, **176**, 231–241.
- 23 S. Patel, S. Kumar, A. Jyoti, B. S. Srinag, R. S. Keshari, R. Saluja, A. Verma, K. Mitra, M. K. Barthwal, H. Krishnamurthy, V. K. Bajpai and M. Dikshit, *Nitric Oxide*, 2010, **22**, 226–234.
- 24 G. Peng, M. F. Montenegro, C. N. M. Ntola, S. Vranic, K. Kostarelos, C. Vogt, M. S. Toprak, T. Duan, K. Leifer, L. Bräutigam, J. O. Lundberg and B. Fadeel, *Nanoscale*, 2020, **12**, 16730–16737.
- 25 A. Manda-Handzlik, W. Bystrzycka, A. Cieloch, E. Glodkowska-Mrowka, E. Jankowska-Steifer, E. Heropolitanska-Pliszka, A. Skrobot, A. Muchowicz, O. Ciepiela, M. Wachowska and U. Demkow, *Cell. Mol. Life Sci.*, 2020, **77**, 3059–3075.
- 26 J. U. Lee, K. Kim and H. Cheong, *2D Mater.*, 2015, **2**, 044003.
- 27 C. Lee, H. Yan, L. E. Brus, T. F. Heinz, J. Hone and S. Ryu, *ACS Nano*, 2010, **4**, 2695–2700.
- 28 S. Carlsson, M. Govoni, N. P. Wiklund, E. Weitzberg and J. O. Lundberg, *Antimicrob. Agents Chemother.*, 2003, **47**, 3713–3718.
- 29 Z. Zhuge, L. L. Paulo, A. Jahandideh, M. C. R. Brandao, P. F. Athayde-Filho, J. O. Lundberg, V. A. Braga, M. Carlström and M. F. Montenegro, *Redox Biol.*, 2017, **13**, 163–169.
- 30 S. Wu, Z. Zeng, Q. He, Z. Wang, S. J. Wang, Y. Du, Z. Yin, X. Sun, W. Chen and H. Zhang, *Small*, 2012, **8**, 2264–2270.
- 31 A. Ambrosi, Z. Sofer and M. Pumera, *Small*, 2015, **11**, 605–612.
- 32 A. Jiang, Y. Zhang, D. Wu, S. Li, Z. Liu, Z. Yang and Z. Wei, *Ecotoxicol. Environ. Saf.*, 2021, **210**, 111886.
- 33 S. Roy, A. Mondal, V. Yadav, A. Sarkar, R. Banerjee, P. Sanpui and A. Jaiswal, *ACS Appl. Bio Mater.*, 2019, **2**, 2738–2755.
- 34 J. Xu, R. Cai, Y. Zhang and X. Mu, *Colloids Surf., B*, 2021, **200**, 111575.
- 35 A. Robert and B. Meunier, *ACS Nano*, 2022, **16**, 6956–6959.
- 36 D. N. Douda, M. A. Khan, H. Grasmann and N. Palaniyar, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 2817–2822.
- 37 K. Bhattacharya, C. Sacchetti, R. El-Sayed, A. Fornara, G. P. Kotchey, J. A. Gaugler, A. Star, M. Bottini and B. Fadeel, *Nanoscale*, 2014, **6**, 14686–14690.
- 38 G. Peng, T. Duan, M. Guo, Y. Xue, C. Chen, Y. Li, K. Leifer and B. Fadeel, *Nanoscale*, 2021, **13**, 13072–13084.
- 39 J. O. Lundberg, M. Carlström and E. Weitzberg, *Cell Metab.*, 2018, **28**, 9–22.
- 40 M. B. Lim, J. W. Kuiper, A. Katchky, H. Goldberg and M. Glogauer, *J. Leukocyte Biol.*, 2011, **90**, 771–776.
- 41 C. F. Urban, U. Reichard, V. Brinkmann and A. Zychlinsky, *Cell. Microbiol.*, 2006, **8**, 668–676.
- 42 B. Lazzaretto and B. Fadeel, *J. Immunol.*, 2019, **203**, 2276–2290.
- 43 M. Jiménez-Alcázar, C. Rangaswamy, R. Panda, J. Bitterling, Y. J. Simsek, A. T. Long, R. Bilyy, V. Krenn, C. Renné, T. Renné, S. Kluge, U. Panzer, R. Mizuta, H. G. Mannherz, D. Kitamura, M. Herrmann, M. Napirei and T. A. Fuchs, *Science*, 2017, **358**, 1202–1206.
- 44 M. J. Kaplan and M. Radic, *J. Immunol.*, 2012, **189**, 2689–2695.
- 45 V. Poli and I. Zanoni, *Trends Microbiol.*, 2023, **31**, 280–293.
- 46 D. Bender and G. Schwarz, *FEBS Lett.*, 2018, **592**, 2126–2139.
- 47 G. Mao, D. Xin, Q. Wang and D. Lai, *Free Radicals Biol. Med.*, 2022, **182**, 79–92.
- 48 M. Cao, R. Cai, L. Zhao, M. Guo, L. Wang, Y. Wang, L. Zhang, X. Wang, H. Yao, C. Xie, Y. Cong, Y. Guan, X. Tao, Y. Wang, S. Xu, Y. Liu, Y. Zhao and C. Chen, *Nat. Nanotechnol.*, 2021, **16**, 708–716.
- 49 G. Schwarz, R. R. Mendel and M. W. Ribbe, *Nature*, 2009, **460**, 839–847.
- 50 L. B. Maia and J. J. Moura, *Chem. Rev.*, 2014, **114**, 5273–5357.
- 51 Y. Li, A. Yamaguchi, M. Yamamoto, K. Takai and R. Nakamura, *J. Phys. Chem. C*, 2017, **121**, 2154–2164.
- 52 Z. Wang, A. von dem Bussche, Y. Qiu, T. M. Valentin, K. Gion, A. B. Kane and R. H. Hurt, *Environ. Sci. Technol.*, 2016, **50**, 7208–7217.
- 53 Y. Sang, W. Li, H. Liu, L. Zhang, H. Wang, Z. Liu, J. Ren and X. Qu, *Adv. Funct. Mater.*, 2019, **29**, 1900518.
- 54 Z. Wang, Q. Tu, S. Zheng, J. J. Urban, S. Li and B. Mi, *Nano Lett.*, 2017, **17**, 7289–7298.
- 55 X. Cong, X. L. Liu, M. L. Lin and P. H. Tan, *npj 2D Mater. Appl.*, 2020, **4**, 13.
- 56 C. Farrera and B. Fadeel, *J. Immunol.*, 2013, **191**, 2647–2656.
- 57 K. Bhattacharya, C. Sacchetti, P. M. Costa, J. Sommertune, B. D. Brandner, A. Magrini, N. Rosato, N. Bottini, M. Bottini and B. Fadeel, *Adv. Healthcare Mater.*, 2018, **7**, e1700916.
- 58 L. C. Potter, P. D. Millington, G. H. Thomas, R. A. Rothery, G. Giordano and J. A. Cole, *FEMS Microbiol. Lett.*, 2000, **185**, 51–57.
- 59 N. Hogg, *Free Radicals Biol. Med.*, 2010, **49**, 122–129.
- 60 J. Joseph, B. Kalyanaraman and J. S. Hyde, *Biochem. Biophys. Res. Commun.*, 1993, **192**, 926–934.

